CXCL12-CXCR4/CXCR7趋化轴在结直肠癌中作用的研究进展  

Roles of the CXCL12-CXCR4/CXCR7 chemokine axis in colorectal carcinoma

作　　者：杨丹[1] 褚晓源[1] 

机构地区：[1]南方医科大学南京临床医学院(南京军区南京总医院)肿瘤内科

出　　处：《医学研究生学报》2015年第1期102-105,共4页Journal of Medical Postgraduates

基　　金：国家自然科学基金(81272394)

摘　　要：结直肠癌(colorectal carcinoma,CRC)是世界上发病率和死亡率最高的恶性肿瘤之一。CRC的侵袭和转移往往是导致治疗失败和死亡的主要原因。既往认为CXCR4是CXCL12的专一受体,最近研究表明,CXCL12还存在着CXCR7这一新受体,这2个受体与CXCL12构成的趋化轴与结直肠癌细胞的增殖、迁移、黏附及肿瘤相关血管生成等密切相关,有可能成为抗肿瘤和抗转移治疗的重要新靶点。Colorectal carcinoma （ CRC ） is one of the malignant tumors with the highest morbidity and mortality rates in the world.The invasion and metastasis of CRC are the major reasons for treatment failure and death .It was believed that CXCR 4 was the exclusive receptor for CXCL12.However, recent studies have identified CXCR7 as a second receptor for CXCL12.Both chemokine ax-es of CXCL12/CXCR4 and CXCL12/CXCR7 closely correlate with the proliferation , migration, adhesion of tumor cells and the forma-tion of tumor-associated vessels in CRC , which may become new significant targets for anti-cancer and anti-metastatic treatment of CRC.

关 键 词：结直肠癌 CXCL12 CXCR4 CXCR7 

分 类 号：R735.3[医药卫生—肿瘤]